Skip to content

Monopar Therapeutics Inc.: 10-Q filed 2019-08-08

What Monopar Therapeutics Inc. reported in its quarterly report filed 2019-08-08 (fiscal Q2 2019): 21 published measures, 69 facts as tagged in accession 0001654954-19-009059.

This filing

Form
10-Q (quarterly report)
Filed
2019-08-08
Fiscal period
fiscal Q2 2019
Accession
0001654954-19-009059 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Monopar Therapeutics Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2019-06-305,595,090USD
At 2018-12-317,317,955USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2019-06-30468,272USD
At 2018-12-31399,551USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2019-06-305,126,818USD
At 2019-03-315,773,818USD
At 2018-12-316,918,404USD
At 2018-09-307,575,884USD
At 2018-06-308,123,630USD
At 2018-03-318,857,579USD
At 2017-12-319,619,400USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2019-06-305,129,828USD
At 2018-12-316,892,772USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-905,700USD91
2019-01-01 to 2019-06-30-2,281,935USD181
2019-01-01 to 2019-03-31-1,376,235USD90
2018-10-01 to 2018-12-31-890,461USD92
2018-07-01 to 2018-09-30-640,184USD92
2018-04-01 to 2018-06-30-820,939USD91
2018-01-01 to 2018-06-30-1,697,287USD181
2018-01-01 to 2018-03-31-876,347USD90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2019-01-01 to 2019-06-30-1,735,707USD181
2018-01-01 to 2018-06-30-1,561,712USD181

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2019-04-01 to 2019-06-300USD91
2019-01-01 to 2019-06-300USD181
2018-04-01 to 2018-06-300USD91
2018-01-01 to 2018-06-300USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2019-01-01 to 2019-06-30-26,177USD181
2018-01-01 to 2018-06-300USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2019-06-30-3,456USD
At 2018-12-31-2,396USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2019-04-01 to 2019-06-30164,600USD91
2019-01-01 to 2019-06-30315,326USD181
2018-04-01 to 2018-06-3026,362USD91
2018-01-01 to 2018-06-3052,514USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-932,109USD91
2019-01-01 to 2019-06-30-2,339,418USD181
2018-04-01 to 2018-06-30-839,997USD91
2018-01-01 to 2018-06-30-1,737,257USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2019-06-305,595,090USD
At 2018-12-317,317,955USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2019-06-30468,272USD
At 2018-12-31399,551USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2019-04-01 to 2019-06-30932,109USD91
2019-01-01 to 2019-06-302,339,418USD181
2018-04-01 to 2018-06-30839,997USD91
2018-01-01 to 2018-06-301,737,257USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2019-04-01 to 2019-06-30329,294USD91
2019-01-01 to 2019-06-301,164,894USD181
2018-04-01 to 2018-06-30492,647USD91
2018-01-01 to 2018-06-30949,788USD181

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2019-06-309,291,421shares
At 2018-12-319,291,421shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2019-06-305,129,828USD
At 2018-12-316,892,772USD
At 2018-06-308,218,641USD
At 2017-12-319,781,925USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2019-06-3029,058,630USD
At 2018-12-3128,567,221USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2019-06-30-23,937,647USD
At 2018-12-31-21,655,712USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2019-04-01 to 2019-06-30-904,633USD91
2019-01-01 to 2019-06-30-2,282,995USD181
2018-04-01 to 2018-06-30-822,518USD91
2018-01-01 to 2018-06-30-1,698,866USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2019-04-01 to 2019-06-30602,815USD91
2019-01-01 to 2019-06-301,174,524USD181
2018-04-01 to 2018-06-30347,350USD91
2018-01-01 to 2018-06-30787,469USD181

Inspect the source

Entity
Monopar Therapeutics Inc. / CIK 0001645469
Captured
2026-09-21T17:22:36.466Z
SEC response SHA-256
11b3f240217511123d89b32408ab3beb4dce0c8844d2a4f4fb7c1085084888d1

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001645469.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))